PM
PLRX icon

Prosight Management’s Pliant Therapeutics PLRX Stock Holding History

Prosight Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1M Buy
1,667,600
+111,856
+7% +$141K 0.34% 32
2025
Q4 		$1.9M Buy
1,555,744
+1,535,257
+7,494% +$2.31M 0.39% 37
2025
Q3 		$30.3K Sell
20,487
-816,913
-98% -$1.25M 0.01% 41
2025
Q2 		$971K Buy
837,400
+503,137
+151% +$711K 0.24% 35
2025
Q1 		$451K Buy
+334,263
New +$2.03M 0.15% 37

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prosight Management's PLRX Position: Q1 2026 in Review

Prosight Management increased its Pliant Therapeutics (PLRX) stake by 7.2% in Q1 2026, buying an estimated $141K and bringing the position to 1,667,600 shares worth $2.1M. The position accounts for 0.34% of the portfolio, ranked #32.

Prosight Management first reported a position in PLRX in Q1 2025 and has held it in 5 quarters since. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Prosight Management held 1,667,600 shares of Pliant Therapeutics worth $2.1M as of Q1 2026.
  • Prosight Management bought 111,856 Pliant Therapeutics shares in Q1 2026, an estimated $141K.
  • Pliant Therapeutics made up 0.34% of Prosight Management's portfolio in Q1 2026, its #32 holding.
  • Prosight Management first reported a position in Pliant Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.